News
11h
TipRanks on MSNAstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer in Cardiovascular Health
The intervention being tested involves the use of Baxdrostat and Dapagliflozin, both administered as tablets. Baxdrostat is being evaluated for its potential to enhance the cardiovascular benefits of ...
10h
TipRanks on MSNAstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...
AstraZeneca PLC (NASDAQ:AZN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. AstraZeneca PLC (NASDAQ:AZN) and ...
In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results